Eli Lilly's Eloratzp cut weight by up to 23.3% over 48 weeks in Phase 2 data
Per Reuters, Eli Lilly reported Phase 2 Eloratzp data in adults with obesity and type 2 diabetes, plus Phase 3 Zepbound results in adolescents.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
Eli Lilly has released Phase 2 data for its drug Eloratzp, which, according to Reuters, showed average weight loss of up to 54.1 lbs (23.3%) over 48 weeks in adults with obesity and type 2 diabetes. The drug also lowered A1C by an average of up to 2.9%, and as many as 77% of participants reached normal blood sugar levels.
The company also reported Phase 3 SURMOUNT-Adolescents results, in which Zepbound reduced BMI by an average of 21.4% in adolescents aged 12 to under 18 with obesity.
why it matters
The news matters to pharma investors because it shows continued progress in Eli Lilly's obesity and diabetes pipeline. Phase 2 results do not equal regulatory approval, and the adolescent findings come from a separate study. Such updates typically move the company's shares and sentiment around rivals in this segment.
market impact
Eli Lilly shares: strong trial data supports expectations for weight-loss drugs
- Eli Lilly shares pressure up — strong trial results on weight loss and blood sugar control
tags
instruments
sources
- Eli Lilly Phase 2 Data Showed Eloratzp Delivered Weight Loss Of Up To Average Of 54.1 Lbs (23.3%) At 48 Weeks In Adults With Obesity, Type 2 Diabetes — Reuters, 14 November 2026 at 17:01 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗